Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for Mereo BioPharma Group (MREO) over the last 2 years, with Dec 2024 value amounting to $1.3 million.

  • Mereo BioPharma Group's Gains from Sales and Divestitures rose 166.89% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 166.89%. This contributed to the annual value of $1.3 million for FY2024, which is 166.89% up from last year.
  • Mereo BioPharma Group's Gains from Sales and Divestitures amounted to $1.3 million in FY2024, which was up 166.89% from $501,380 recorded in FY2023.
  • Mereo BioPharma Group's 5-year Gains from Sales and Divestitures high stood at $1.3 million for FY2024, and its period low was $501,380 during FY2023.
  • In the last 2 years, Mereo BioPharma Group's Gains from Sales and Divestitures had a median value of $919,765 in 2023 and averaged $919,765.
  • Data for Mereo BioPharma Group's Gains from Sales and Divestitures shows a peak YoY surged of 166.89% (in 2024) over the last 5 years.
  • Over the past 2 years, Mereo BioPharma Group's Gains from Sales and Divestitures (Yearly) stood at $501,380 in 2023, then soared by 166.89% to $1.3 million in 2024.